Download PDF
Arzneimittelforschung 2010; 60(6): 354-361
DOI: 10.1055/s-0031-1296300
Ferric Carboxymaltose
Editio Cantor Verlag Aulendorf (Germany)

In vitro studies of ferric carboxymaltose on placental permeability using the dual perfusion model of human placenta

Antoine Malek
Department of Obstetrics and Gynecology, Inselspital, University of Berne, Switzerland   Department of Obstetrics, University Hospital Zurich, Switzerland
› Author Affiliations
Further Information

Publication History

Publication Date:
21 December 2011 (online)

    Permissions and Reprints

Abstract

An in vitro perfusion model of human placenta was used to study the transplacental passage of iron applied in the form of the drug compound ferric carboxymaltose (FCM) which had been radio-labelled with 59Fe. In four placental perfusion experiments, two simulated circuits for the maternal and fetal sides of the placenta were set up with two experimental phases each lasting 3 h. FCM was added to the maternal circuit at the beginning of each phase to a final iron concentration of 11 mM, which is at least 10 times higher than the maximal predicted level in blood after an administration of 200 mg iron as FCM. The effects of adding transferrin at a physiological concentration of 1.67 mg/ ml were also tested.

The concentration profiles of 59Fe showed a 10% decrease within the first 30 min of perfusion on the maternal side. Thereafter the radioactivity levels remained unchanged. The addition of transferrin had no effect on the tissue uptake of 59Fe-FCM. No transferred iron radioactivity could be detected in the fetal circuit. Despite a loss of approximately 10% of the radio-labelled iron observed on the maternal side, only 0.5‒2% of the radioactivity was detected in the placental tissue after perfusion.

No free iron could be detected at the end of perfusion on the maternal side using ultrafiltration or acid precipitation methods. In addition, the production of transferrin receptor remained unchanged, with similar concentrations in placental tissue before and after perfusion.

No effects of FCM on placental viability were observed in terms of energy metabolism (glucose consumption and lactate production), hormone release or placental permeability (assessed by the transfer rates of creatinine and antipyrine). However, two additional observations were made: firstly, a significant reduction in the rate of cell death compared to control conditions was observed in the presence of FCM; secondly, the integrity of the fetal capillary system was improved on the fetal side of the perfusion system. It is concluded that the iron compound FCM does not cross the placenta and may increase the integrity of placental tissue (at least under in vitro conditions), but this latter observation needs further investigation.

Key words

Anaemia - Ferinject® - Ferric carboxymaltose, - placental permeability - Intravenous iron - Iron deficiency
 

  • References

  • 1 Dallman PR. Biochemical basis for the manifestations of iron deficiency. Annu Rev Nutr. 1986; 6: 13-40
    CrossrefPubMedGoogle Scholar
  • 2 Lozoff B, Jimenez E, Hagen J, Mollen E, Wolf AW. Poorer behavioral and developmental outcome more than 10 years after treatment for iron deficiency in infancy. Pediatrics. 2000; 105: E51 [cited: 4 April 2000]. Available from: www.pediatrics.org/cgi/content/full/105/4/e51
    CrossrefPubMedGoogle Scholar
  • 3 Walter T, De Andraca I, Chadud P, Perales CG. Iron deficiency anemia: adverse effects on infant psychomotor development. Pediatrics. 1989; 84: 7-17
    PubMedGoogle Scholar
  • 4 Felt BT, Lozoff B. Brain iron and behavior of rats are not normalized by treatment of iron deficiency anemia during early development. J Nutr. 1996; 126: 693-701
    PubMedGoogle Scholar
  • 5 Yip R. Iron. In: Bowman B, Russell RM. editors Present knowledge in nutrition. 8th ed Washington DC: ILSI Press; 2001. p. 311-318
    Google Scholar
  • 6 Perry GS, Yip R, Zyrkowski C. Nutritional risk factors among low-income pregnant US women: The Centers for Disease Control and Prevention (CDC) Pregnancy Nutrition Surveillance System, 1979-1993. Sem Perinatol. 1995; 19: 211-21
    CrossrefPubMedGoogle Scholar
  • 7 Scholl TO, Hediger ML. Anemia and iron-deficiency anemia: compilation of data on pregnancy outcome. Am] Clin Nutr. 1994; 59 (Suppl) 492S-501S
    PubMedGoogle Scholar
  • 8 Institute of Medicine, Subcommittee on Nutritional Status and Weight Gain during Pregnancy. Nutrition during pregnancy. Washington DC: National Academy Press; 1990.
    PubMed
  • 9 Scholl TO. Iron status during pregnancy: setting the stage for mother and infant. Am J Clin Nutr. 2005; 81: 1218S-1222S
    PubMedGoogle Scholar
  • 10 Casanueva E, Viteri FE. Iron and oxidative stress in pregnancy. J Nutr. 2003; 133 (5 Suppl 2) 1700S-1708S
    PubMedGoogle Scholar
  • 11 Bemotti S, Seidman E, Sinnett D, Brunet S, Dionne S, Delvin E, Levy E. Inflammatory reaction without endogenous antioxidant response in Caco-2 cells exposed to iron/as-corbate-mediated lipid peroxidation. Am J Physiol Gastro-intest Liver Physiol. 2003; 285: G898-906
    PubMedGoogle Scholar
  • 12 Carrier J, Aghdassi E, Platt I, Cullen J, Allard IP. Effect of oral iron supplementation on oxidative stress and colonic inflammation in rats with induced colitis. Aliment Pharmacol Ther. 2001; 15: 1989-99
    CrossrefPubMedGoogle Scholar
  • 13 Schneider H, Panigel M, Dancis J. Transfer across the perfused human placenta of antipyrine, sodium, and leucine. Am J Obstet Gynecol. 1972; 114: 822-8
    PubMedGoogle Scholar
  • 14 Di Santo S, Malek A, Sager R, Andres AC, Schneider H. Trophoblast viability in perfused term placental tissue and explant cultures limites to 7–24 hours. Placenta. 2003; 24: 882-94
    CrossrefPubMedGoogle Scholar
  • 15 Malek A, Bersinger NA, Di Santo S, Mueller MD, Sager R, Schneider H et al. C-reactive protein production in term human placental tissue. Placenta. 2006; 27: 619-25
    CrossrefPubMedGoogle Scholar
  • 16 Malek A, Sager R, Altermatt HJ, Gaeng D, Leiser R, Schneider H. Glucose consumption and lactate production of human placental tissue under different conditions of in vitro incubation. J Soc Gynecol Investig. 1996; 3: 113-20
    CrossrefPubMedGoogle Scholar
  • 17 Malek A, Sager R, Lang AB, Schneider H. Protein transport across the in vitro perfused human placenta. Am J Reprod Immunol. 1997; 38: 263-71
    CrossrefPubMedGoogle Scholar
  • 18 Wier PJ, Miller RK. Oxygen transfer as an indicator of perfusion variability in the isolated human placental lobule. Contrib Gynecol Obstet. 1985; 13: 127-31
    PubMedGoogle Scholar
  • 19 Mose T, Mortensen GK, Hedegaard M, Knudsen LE. Phthalate monoesters in perfusate from a dual placenta perfusion system, the placenta tissue and umbilical cord blood. Reprod Toxicol. 2007; 23: 83-91
    CrossrefPubMedGoogle Scholar
  • 20 Malek A, Leiser R. Influence of the magnesium aspartate hydrochloride administration to the maternal circuit on the aspartate concentration of the fetal circuit under in vitro perfusion of human placenta. Eur J Obstet Gynecol Reprod Biol. 2009; 142: 12-17
    CrossrefPubMedGoogle Scholar
  • 21 Schneider H, Dancis J. In vitro human placental perfusion of human placenta. Trophoblast Res. 1987; 2: 597-605
    PubMedGoogle Scholar
  • 22 Bajoria R, Fisk NM. Permeability of human placenta and fetal membranes to thyrotropin-stimulating hormone in vitro. Pediatr Res. 1998; 43: 621-8
    PubMed
  • 23 Schmolling J, Brunken M, Richter O, Ulrich U, Schmidt S, Krebs D. Photoradiation of perfused placental tissue –a suitable in vitro model for photodynamic therapy?. Arch Gynecol Obstet. 2001; 265: 199-2003
    CrossrefPubMedGoogle Scholar
  • 24 Brodie BB. The estimation of antipyrine in biological materials. J Biol Chem. 1949; 179: 25-9
    PubMedGoogle Scholar
  • 25 Malek A, Sager R, Willi A, Müller J, Hänggi W, Leiser R et al. Production of protein hormones by cultured tropho-blast cells isolated from term and early placentae. Am J Reprod Immunol. 2000; 43: 278-84
    CrossrefPubMedGoogle Scholar
  • 26 Malek A, Willi A, Müller J, Sager R, Hänggi W, Bersinger N. Capacity for hormone production of cultured trophoblast cells obtained from placentae at term and in early pregnancy. J Assist Reprod Genet. 2001; 18: 299-304
    CrossrefPubMedGoogle Scholar
  • 27 Malek A, Sager R, Zakher A, Schneider H. Transport of immunoglobulin G and its subclasses across the in vitro-perfused human placenta. Am J Obstet Gynecol. 1995; 173: 760-7
    CrossrefPubMedGoogle Scholar
  • 28 Malek A, Sager R, Kuhn P, Nicolaides KH, Schneider H. Evolution of maternofetal transport of immunoglobulins during human pregnancy. Am J Reprod Immunol. 1996; 36: 248-55
    CrossrefPubMedGoogle Scholar
  • 29 Malek A, Leiser R. Influence of the magnesium aspartate hydrochloride administration to the maternal circuit on the aspartate concentration of the fetal circuit under in vitro perfusion of human placenta. Eur J Obstet Gynecol Reprod Biol. 2009; 142: 12-7
    CrossrefPubMedGoogle Scholar
  • 30 Myren M, Mose T, Mathiesen L, Knudsen LE. The human placenta –an alternative for studying foetal exposure. Toxicol In Vitro. 2007; 21: 1332-40
    CrossrefPubMedGoogle Scholar
  • 31 Crichton RR, Danielson BG, Geisser P. Iron therapy with special emphasis on intravenous administration. 4th ed Bremen (Germany): UNI-MED; 2008
    Google Scholar
  • 32 Malek A, Sager R, Zakher A, Schneider H. Transport of immunoglobulin G and its subclasses across the in vitro-perfused human placenta. Am J Obstet Gynecol. 1995; 173: 760-7
    CrossrefPubMedGoogle Scholar